Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 in Combination With a Statin in Patients With Hypercholesterolaemia (LAPLACE-TIMI 57): A Randomised, Placebo-Controlled, Dose-Ranging, Phase 2 Study

Study Questions:

How safe and effective is antibody-mediated inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with hypercholesterolemia on statin therapy?